

**Amendments to the Specification:**

Please add the following new paragraph on page 1 at line 3, under the title:

This is a divisional application of U.S. Application No. 09/701,623 filed December 1, 2000, which is a national stage application of International Application No. PCT/US99/13959 filed June 21, 1999, which is a continuation-in-part of U.S. Application No. 09/100,287 file June 20, 1998, each of which is incorporated by reference herein in its entirety.

Please replace the first paragraph on page 19 with the following amended paragraph:

follows the Rothbard sequence and the 1, 4, 5, 8 rule:

1	5	10	15
Asp-Leu-Ser-Asp-Leu-Lys-Gly-Leu-Leu-Leu-His-Lys-Leu-Asp-Gly-Leu			
Glu Ile	Glu Ile Arg	Ile Ile Ile	Arg Ile Glu Ile
Val	Val	Val Val Val	Val Val
Phe	Phe	Phe Phe Phe	Phe Phe

Please replace the first full paragraph on page 35 with the following amended paragraph:

The Th epitope is attached, optionally through spacer B, to either the N terminus or C terminus of the IgE-CH3 peptide and crossreactive and functional immunological analogs thereof. Preferred peptide immunogens of this invention are the peptides containing the IgE-CH3 domain antigen peptides (*e.g.*, SEQ ID NO:5) (or immunological analogs thereof) and Th peptides, and optionally Inv (SEQ ID NO:13). In a more preferred embodiment the Th epitope is an HBs Th, HBc Th, MV<sub>F</sub> Th, PT

Th, TT Th, CT Th (*e.g.*, SEQ ID NO:12) or artificial Th (SEQ ID NOS:9-11 and 60), or functional immunogenic analogue thereof, and optionally, A is Inv (SEQ ID NO:13) attached through a (B)<sub>n</sub> spacer such as Gly-Gly or ([□] ε-N)Lys.